

Details on abstracts listed above and additional key abstracts for Merck

Bladder cancer	
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, Phase 3 KEYNOTE-B15 study. M. D. Galsky.1	Abstract #LBA630, Oral abstract session B: Urothelial carcinoma
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from the Phase 2 2870-002/SKB264-II-06 study. X. Bian.3	Abstract #744, Poster session B: Prostate cancer and urothelial carcinoma
Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. To be determined.1	Abstract #638, Rapid oral abstract session B: Urothelial carcinoma
KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC). A. Peer.1	Abstract #634, Rapid oral abstract session B: Urothelial carcinoma
SWOG 2427: Single arm Phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT). L. K. Ballas.4	Abstract #TPS913, Trials in progress poster session B: Urothelial carcinoma
Kidney cancer	
Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized Phase 3 LITESPARK-022 study. T. K. Choueiri.	Abstract #LBA418, Oral abstract session C: Renal cell cancer and testicular cancer
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label Phase 3 LITESPARK-011 study. R. J. Motzer.2	Abstract #LBA417, Oral abstract session C: Renal cell cancer and testicular cancer
Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study Part 1. D. F. McDermott.5	Abstract #423, Rapid oral abstract session C: Renal cell cancer and testicular cancer
KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC). L. Albiges.	Abstract #505, Poster session C: Renal cell cancer; adrenal, penile, testicular and urethral cancers
Phase 2 trial of belzutifan in participants from China and Japan with von Hippel-Lindau disease-associated tumors: Results from LITESPARK-015 cohort B1. G. Naik.	Abstract #494, Poster session C: Renal cell cancer; adrenal, penile, testicular and urethral cancers
Prostate cancer	
Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). H. Beltran.6	Abstract #182, Poster session A: Prostate cancer

1 In collaboration with Astellas/Pfizer

2 In collaboration with Eisai

3 Led by Kelun-Biotech, conducted in China

4 Sponsored by National Cancer Institute

5 In collaboration with Pfizer

6 In collaboration with Daiichi Sankyo